OBJECTIVE: Characterization of pharmacokinetics (PK) is lacking for vaginal progesterone in pregnancy. Dosing of vaginal progesterone for preterm birth prevention has been empirical. Outside of pregnancy, vaginal progesterone dosing results in peak serum levels at 8-12 hours. However, due to pregnancy related changes in hepatic metabolism, renal clearance, and endogenous serum progesterone, studies outside of pregnancy may not apply in pregnancy. Lack of basic PK data on vaginal progesterone in pregnancy limits our ability to evaluate appropriate dosing or compare formulations. The objective of this study is to determine the PK of vaginal progesterone in the second trimester of pregnancy. STUDY DESIGN: This is a prospective pilot study of 6 low risk singletons 18 0/7-23 6/7 weeks' with BMI 20-40. Exclusion criteria were current vaginitis, abnormal pap smear, prescription medication use, cervical length 25mm, prior preterm birth, and contraindication to progesterone. Participants received a single dose of 200mg micronized vaginal progesterone and serum progesterone levels were evaluated every two hours from 0 to 12hours and then 24 hours post-dose. Primary outcome was concentration time/plot of serum progesterone. Progesterone concentration assayed with validated electrochemiluminescence immunoassay (ECLIA, Roche). RESULTS: Mean age was 27AE6.4 years, mean BMI 26.6AE3.3kg/m 2 , and mean gestational age was 22.3AE1.3 weeks. One participant (ID 1, Figure 1 ) had a peak plasma level which deviated significantly (>2SD) from other participants' , thus median values were used for summary statistics. Median baseline serum progesterone was 47.3 [12] ng/ml, median peak concentration was 54.3[19.9] ng/ml, mean time to peak was 12[5] hours and mean difference from baseline to peak was 10.5[19.5] ng/ml. Median area under the curve was 112.1 [281.9] ng*h/ml. Median change in serum progesterone from baseline concentration time plot in Figure 2 . CONCLUSION: PK of vaginal progesterone in pregnancy differs from outside of pregnancy. There is a trend of rising serum progesterone over baseline levels but with significant inter-individual variability. A larger study with serial serum progesterone over 24 hours should be conducted to establish parameters for systemic absorption of vaginal progesterone or establish that vaginal progesterone does not impact systemic progesterone levels in pregnancy and therefore acts locally. OBJECTIVE: It is postulated that the vaginal microbiome lends to the risk/prediction of preterm birth (PTB), although data demonstrating this is inconsistent. As microbiome function results from production of strain-specific metabolites, it is important to adequately characterize vaginal ecology at the strain level. Reliable strain detection requires deep metagenomic sequencing, which cannot be achieved with 16S approaches. Here we tested the hypothesis that keystone vaginal bacterial species are present as dissimilar strains that might differentially associate with PTB. STUDY DESIGN: In this prospective study we performed metagenomic sequencing (Illumina HiSeq) on microbial DNA extracted from vaginal samples (n¼201, 60 gravidae) collected during 3rd trimester, delivery, and 4-6 weeks postpartum. Strain-level classification of bacteria was performed using PanPhlAn. RESULTS: Lactobacillus spp. are present as one of two strains, whereas Gardnerella vaginalis comprises five strains ( Fig1A). When we then examined interactions at the strain level, we found strain modeling mirrored species level co-occurrence models. However, we found L. crispatus and L. jensenii strains negatively co-occurred with Gardnerella strains; at the species level L. iners negatively and positively co-occurred with Gv2b and Gv3 strains, respectively (Fig1B). As exclusionary interactions between these taxa are thought to lead to PTB, we tested whether differences in strain frequencies associated with PTB. There was no significant difference in the frequency of multiple Gardnerella strains during pregnancy on PTB. When we examined the frequency of Gardnerella and lactobacilli strains, we also failed to identify clear associations with PTB (p>0.05) (Fig1C). CONCLUSION: Metagenomic sequencing, although costlier and more computationally intensive compared to 16S metabarcoding, provides a highly sensitive method for detecting the dominant members of the vaginal microbiome, enabling strain-level differentiation. The current findings are noteworthy, as they demonstrate for the first time the degree to which strain-level differences Poster Session II ajog.org
OBJECTIVE: Characterization of pharmacokinetics (PK) is lacking for vaginal progesterone in pregnancy. Dosing of vaginal progesterone for preterm birth prevention has been empirical. Outside of pregnancy, vaginal progesterone dosing results in peak serum levels at 8-12 hours. However, due to pregnancy related changes in hepatic metabolism, renal clearance, and endogenous serum progesterone, studies outside of pregnancy may not apply in pregnancy. Lack of basic PK data on vaginal progesterone in pregnancy limits our ability to evaluate appropriate dosing or compare formulations. The objective of this study is to determine the PK of vaginal progesterone in the second trimester of pregnancy. STUDY DESIGN: This is a prospective pilot study of 6 low risk singletons 18 0/7-23 6/7 weeks' with BMI 20-40. Exclusion criteria were current vaginitis, abnormal pap smear, prescription medication use, cervical length 25mm, prior preterm birth, and contraindication to progesterone. Participants received a single dose of 200mg micronized vaginal progesterone and serum progesterone levels were evaluated every two hours from 0 to 12hours and then 24 hours post-dose. Primary outcome was concentration time/plot of serum progesterone. Progesterone concentration assayed with validated electrochemiluminescence immunoassay (ECLIA, Roche). RESULTS: Mean age was 27AE6.4 years, mean BMI 26.6AE3.3kg/m 2 , and mean gestational age was 22.3AE1.3 weeks. One participant (ID 1, Figure 1) Figure 2 . CONCLUSION: PK of vaginal progesterone in pregnancy differs from outside of pregnancy. There is a trend of rising serum progesterone over baseline levels but with significant inter-individual variability. A larger study with serial serum progesterone over 24 hours should be conducted to establish parameters for systemic absorption of vaginal progesterone or establish that vaginal progesterone does not impact systemic progesterone levels in pregnancy and therefore acts locally.
477 Microbial strain ecology of the vaginal microbiome in pregnancy and at postpartum
Baylor College of Medicine, Houston, TX OBJECTIVE: It is postulated that the vaginal microbiome lends to the risk/prediction of preterm birth (PTB), although data demonstrating this is inconsistent. As microbiome function results from production of strain-specific metabolites, it is important to adequately characterize vaginal ecology at the strain level. Reliable strain detection requires deep metagenomic sequencing, which cannot be achieved with 16S approaches. Here we tested the hypothesis that keystone vaginal bacterial species are present as dissimilar strains that might differentially associate with PTB. STUDY DESIGN: In this prospective study we performed metagenomic sequencing (Illumina HiSeq) on microbial DNA extracted from vaginal samples (n¼201, 60 gravidae) collected during 3rd trimester, delivery, and 4-6 weeks postpartum. Strain-level classification of bacteria was performed using PanPhlAn. RESULTS: Lactobacillus spp. are present as one of two strains, whereas Gardnerella vaginalis comprises five strains ( Fig1A). When we then examined interactions at the strain level, we found strain modeling mirrored species level co-occurrence models. However, we found L. crispatus and L. jensenii strains negatively co-occurred with Gardnerella strains; at the species level L. iners negatively and positively co-occurred with Gv2b and Gv3 strains, respectively (Fig1B). As exclusionary interactions between these taxa are thought to lead to PTB, we tested whether differences in strain frequencies associated with PTB. There was no significant difference in the frequency of multiple Gardnerella strains during pregnancy on PTB. When we examined the frequency of Gardnerella and lactobacilli strains, we also failed to identify clear associations with PTB (p>0.05) (Fig1C). CONCLUSION: Metagenomic sequencing, although costlier and more computationally intensive compared to 16S metabarcoding, provides a highly sensitive method for detecting the dominant members of the vaginal microbiome, enabling strain-level differentiation. The current findings are noteworthy, as they demonstrate for the first time the degree to which strain-level differences Poster Session II among dominant vaginal microbial species occur. The failure to see an association with PTB and strains likely explains the evident disparity among others PTB studies. Given these strain-level differences, we speculate larger studies will be required to definitively determine whether an association between the vaginal microbiome and PTB exists. The study population compromised 27,524 births, of which 2.9% were early preterm and 7.1% late preterm. Six percent (n¼1655) of newborns were exposed to antenatal steroids including 1.9% (n¼530) in the late preterm period. Of 530 exposed to late preterm steroids, 20.2% had one or more guideline-endorsed exclusion to their use, 17.2% delivered at term and 16.6% were born on the same day as steroids were given. (Table 1 ) Overall, 25.7% of guideline -eligible late preterm newborns were exposed to late preterm steroids and use varied with gestational age. (Figure 1 ) At level 1 hospitals, 3.7% of late preterm births without exclusions received late preterm steroids, compared to 18.3% at level 2 hospitals, and 30.6% at level 3 or 4 hospitals (p<0.001). Almost 90% of late preterm steroids given outside the guidelines were at level 3 or 4 hospitals. CONCLUSION: Subsequent to the 2016 national guidelines, late preterm steroids have contributed substantially to antenatal steroid use and represent 1/3 of all antenatal steroids given in 2017. However, implementation has not been optimal with 1/5 cases given outside the guideline recommendations and only 25% of the target late preterm population receiving late preterm steroids.
